A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Cancer Cell

Volumn 18, Issue 1, 2010, Pages 63-73

  Puyol, Marta ^a,d   Martín, Alberto ^a,e   Dubus, Pierre ^b   Mulero, Francisca ^a   Pizcueta, Pilar ^a   Khan, Gulfaraz ^c   Guerra, Carmen ^a   Santamaría, David ^a   Barbacid, Mariano ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN INTERACTION; SENESCENCE; TUMOR GROWTH;

EID: 77954279920     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.05.025     Document Type: Article

References (35)

1. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
2. Barrière C., Santamaría D., Cerqueira A., Galán J., Martín A., Ortega S., Dubus P., Malumbres M., Barbacid M. Mice thrive without Cdk4 and Cdk2. Mol. Oncol. 2007, 1:72-83.
3. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
4. Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sánchez-Céspedes M.A. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 2009, 30:1199-1206.
5. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., Schleker T., Perna D., Tronnersjö S., Murga M., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol. 2010, 12:54-59.
6. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., et al. Tumour biology: Senescence in premalignant tumours. Nature 2005, 436:642.
7. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
8. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., Albassam M., Zheng X., Leopold W.R., Pryer N.K., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
9. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., Campuzano V., Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
10. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 2005, 65:10280-10288.
11. Landis M.W., Pawlyk B.S., Li T., Sicinski P., Hinds P.W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006, 9:13-22.
12. Lapenna S., Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 2009, 8:547-566.
13. Li J., Zhang Z., Dai Z., Plass C., Morrison C., Wang Y., Wiest J.S., Anderson M.W., You M. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 2003, 22:1243-1246.
14. Mallette F.A., Gaumont-Leclerc M.F., Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007, 21:43-48.
15. Malumbres M., Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9:153-166.
16. Malumbres M., Sotillo R., Santamaría D., Galán J., Cerezo A., Ortega S., Dubus P., Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118:493-504.
17. Malumbres M., Pevarello P., Barbacid M., Bischoff J.R. CDK inhibitors in cancer therapy: What is next?. Trends Pharmacol. Sci. 2008, 29:16-21.
18. Martín A., Odajima J., Hunt S.L., Dubus P., Ortega S., Malumbres M., Barbacid M. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005, 7:591-598.
19. Miliani de Marval P.L., Macias E., Rounbehler R., Sicinski P., Kiyokawa H., Johnson D.G., Conti C.J., Rodriguez-Puebla M.L. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol. Cell. Biol. 2004, 24:7538-7547.
20. Ortega S., Prieto I., Odajima J., Martín A., Dubus P., Sotillo R., Barbero J.L., Malumbres M., Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35:25-31.
21. Palmero I., Pantoja C., Serrano M. p19ARF links the tumor suppressor p53 to Ras. Nature 1998, 395:125-126.
22. Pontano L.L., Aggarwal P., Barbash O., Brown E.J., Bassing C.H., Diehl J.A. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic instability. Mol. Cell. Biol. 2008, 28:7245-7258.
23. Prieur A., Peeper D.S. Cellular senescence in vivo: A barrier to tumorigenesis. Curr. Opin. Cell Biol. 2008, 20:150-155.
24. Rane S.G., Dubus P., Mettus R.V., Galbreath E.J., Boden G., Reddy E.P., Barbacid M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet. 1999, 22:44-52.
25. Rodriguez-Puebla M.L., Miliani de Marval P.L., LaCava M., Moons D.S., Kiyokawa H., Conti C.J. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am. J. Pathol. 2002, 161:405-411.
26. Santamaría D., Barrière C., Cerqueira A., Hunt S., Tardy C., Newton K., Cáceres J.F., Dubus P., Malumbres M., Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007, 448:811-815.
27. Scholl C., Fröhling S., Dunn I.F., Schinzel A.C., Barbie D.A., Kim S.Y., Silver S.J., Tamayo P., Wadlow R.C., Ramaswamy S., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
28. To M.D., Wong C.E., Karnezis A.N., Del Rosario R., Di Lauro R., Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 2008, 40:1240-1244.
29. Tsutsui T., Hesabi B., Moons D.S., Pandolfi P.P., Hansel K.S., Koff A., Kiyokawa H. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol. 1999, 19:7011-7019.
30. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004, 5:375-387.
31. Uchiyama M., Usami N., Kondo M., Mori S., Ito M., Ito G., Yoshioka H., Imaizumi M., Ueda Y., Takahashi M., et al. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. Int. J. Cancer 2003, 107:962-969.
32. Webley K., Bond J.A., Jones C.J., Blaydes J.P., Craig A., Hupp T., Wynford-Thomas D. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 2000, 20:2803-2808.
33. Ye X., Zhu C., Harper J.W. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proc. Natl. Acad. Sci. USA 2001, 98:1682-1686.
34. Yu Q., Sicinska E., Geng Y., Ahnström M., Zagozdzon A., Kong Y., Gardner H., Kiyokawa H., Harris L.N., Stål O., et al. Requirement for Cdk4 kinase function in breast cancer. Cancer Cell 2006, 9:23-32.
35. Zhang Z., Wang Y., Vikis H.G., Johnson L., Liu G., Li J., Anderson M.W., Sills R.C., Hong H.L., Devereux T.R., et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 2001, 29:25-33.